Phil Nadeau, Ph.D.

Managing Director, Health Care - Biotechnology

Headshot photo of Phil Nadeau

Philip Nadeau is a managing director and senior research analyst on the biotechnology team at Cowen. He joined Cowen in 2000 and is responsible for covering approximately 25 large-, mid-, and small-cap biotechnology stocks. Cowen’s biotechnology team has consistently been among the top-ranked teams in the Greenwich Survey. Dr. Nadeau has been recognized in The Wall Street Journal’s “Best on the Street” rankings and in the Institutional Investor poll. His views on biotechnology topics are often quoted by national news services such as Reuters, Bloomberg and the Dow Jones newswires. Prior to joining Cowen, he was a research assistant at Children’s Hospital, Boston.

Dr. Nadeau has an SB/MEng in electrical engineering and computer science from MIT and a Ph.D. in Neurobiology from Harvard University. 

Get In Touch

Start a conversation with Phil Nadeau

    Insights

    Explore related thought leadership, reports, coverage and insights for Phil Nadeau.

    Man looking at screen, in the reflection of his eye glasses is info related to BioTech and Health care. Representative of investing in a biotech.
    Ahead of the Curve®

    Generalist’s Guide to Vetting Smid-Cap Biotech: Bear Market Edition

    Read More >
    Petri dish of pills under FDA review. Representative of navigating FDA regulation post Covid.
    Ahead of the Curve®

    Trials & Triumphs of the FDA: What Matters? Where are We?

    Read More >
    Ahead of the Curve®

    This Biotech Bear Market Too Shall Pass

    Read More >

    Research Contacts

    Our Research team is led by seasoned, entrepreneurial-minded individuals who are driven by a relentless curiosity to redefine expectations.

    Meet Our People
    Senior businessman handshaking with young woman in the office